 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C25H30O4S |
| Molar mass | 426.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mespirenone (INN; developmental codeZK-94679; also known asΔ1-15β,16β-methylenespironolactone) is asteroidalantimineralocorticoid of thespirolactone group related tospironolactone that was never marketed.[1][2] Animal research found that it was 3.3-fold more potent as an antimineralocorticoid relative to spironolactone.[3] In addition to its antimineralocorticoid properties, mespirenone is also aprogestogen,antigonadotropin, andantiandrogen.[2][4] It is 2- to 3-fold as potent as spironolactone as a progestogen and antigonadotropin but its antiandrogenic activity is markedly reduced and weak (though still of significance) in comparison.[4][5] Mespirenone is also apotent and specificenzyme inhibitor of18-hydroxylase and thus ofmineralocorticoidbiosynthesis.[6] The drug was under development bySchering (nowBayer Schering Pharma) and reachedphase IIclinical trials but was discontinued in 1989.[7]
